The following was sent to me as a comment to a prior post. Instead, I think the comment warrants being put up as its own separate post. It is written by a urologist who has requested that I only use his initials instead of his full name. I would like to thank you for your [...]
Roche Pharmaceuticals has reported that their clinical trial of Avastin in men with advanced prostate cancer did not improve their overall life expectancy. […]
The drug is called Cabazitaxel, (it will be named Jevtana) and is made by the French company Sanofi-Aventis SA. Cabazitaxel is a chemical cousin of Taxotere (the current standard of care) and it is designed to evade the mechanism that cancer cells use to resist Taxotere, so we can assume that initially it would be [...]
We know that docetaxel chemotherapy (chemo) extends life, but which men might hope to experience an increase in survival? The Department of Urology, All India Institute of Medical Sciences, New Delhi, India performed a small study designed to evaluate the efficacy of docetaxel/prednisone and zoledronic acid in the treatment of men with hormone refractory prostate [...]
Provenge, a cancer vaccine, has demonstrated its ability to improve the survival of men with castrate resistant prostate cancer (CRPC). The developer, Dendreon, has submitted it latest clinical trial data to the FDA for approval. We hope to have an approval by mid-year 2010. Growth factors were thought to be potential targets for treating prostate [...]